CloneID: COL-1
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by immunizing BALB/c mice with extracts or membrane-enriched fractions of biopsy material from either primary or metastatic colon carcinoma lesions.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format for improved compatibility with existing reagents assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q13984
Specificity Statement: The antibody is specific for CEA. COL-1 does not cross-react with NCA, NFA-1, BGP and PMNs. CEA is one of the most commonly used tumor markers in serum immunoassay determinations of carcinoma.
Application Notes (Clone): The antibody reacted with purified carcinoembryonic antigen in solid-phase radioimmunoassay and by Western Blot analysis. The antibody was tested by fluorescence-activated cell sorting for cell surface binding to the LS174T WiDr and HT-29 colon carcinoma cell lines. The antibody was tested by FACS for binding to the surface of normal human polymorphonuclear leukocytes where it appeared nonreactive (Muraro et al., 1985; PMID: 2413997). The antibody was shown to bind CEA with a Ka of 1.4 x 10^9 M^-1 (Kuroki et al., 1989; PMID: 2474516). The antibody was used for immunohistochemistry on colorectal, gastric, and lung adenocarcinoma tumor tissues. In addition, pancreatic, breast, gallbladder, bile duct, malignant ovarian teratoma, mucinous endometrial carcinoma, colon cancer, remote colon mucosa and bladder cancer stained positive (Shi et al., 1994; PMID: 7520463 and Robbins et al., 1993; PMID: 8386136). The antibody reacted by immunofluorescence with a mouse colon adenocarcinoma MC-38 expressing high levels of cell-surface CEA cell line, but not with the NCA or BGP transfectants (Robbins et al., 1993; PMID: 8386136). 125I-labeled COL-1 IgG was shown to efficiently and specifically target the LS-174T human colon carcinoma xenograft in athymic mice. 131I-labeled COL-1 demonstrated a reduction of tumor growth rate in the same model (Siler et al., PMID: 8292968). I131-labeled COL-1 was tested in phase I trial in patients with gastrointestinal malignancies (Yu et al. 1996). The humanized version of the antibody was constructed and used in the detection and treatment of a CEA-expressing tumor (US8828717B2).
English
Deutsch
